Are Early Access Programmes the Better Funding Pathway for Biotechs?
Many biotech executives we currently meet report difficulties in securing their next financing round to fund further clinical development and
Navigating the DiGA Pathway in Germany in 2025: A Comprehensive Guide for MedTechs
What is DiGA in short? DiGA, short for Digitale Gesundheitsanwendungen, translates to Digital Health Applications in English. The DiGA pathway
2025 U.S. Most Favored Nation Policy: Implications and Strategic Guidance for Pharma and Biotech
The U.S. pharmaceutical landscape is set for another major shift. On May 12th, President Trump signed a new Executive Order
New 2025 French AP early access program covers nearly 370 innovative treatments
France’s Reimbursed Early Access Programs (EAP) provide opportunities for reimbursement of new and innovative drugs that treat serious diseases before
2025 EU HTA: Launching a New Era in Joint Clinical Assessments
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the European Union’s Health Technology Assessment
New Technology Add-On Payment (NTAP) 2025 – Key insights
What is NTAP The New Technology Add-On Payment (NTAP) is a reimbursement program under the Centers for Medicare & Medicaid
